About Dr. Bryan Burt
Bryan M. Burt is an Assistant Professor of Surgery in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine. Dr. Burt is Associate Chief of the Division of Thoracic Surgery, and Director of Thoracic Surgery Research at Baylor. Dr. Burt received his medical degree from Cornell University School of Medicine, and completed training in general surgery and thoracic surgery at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Burt’s clinical practice includes the care of patients with thoracic malignancies and benign diseases of the esophagus, thoracic outlet, and chest wall. His clinical research interests include clinical effectiveness studies in minimally invasive approaches to thoracic malignancies. His interest in translational science is fulfilled by his clinical trials of immunotherapy for thoracic malignancies, and his studies of tumor immunology and novel therapeutic immunotherapies for lung cancer and mesothelioma. Dr. Burt serves on the editorial board of the Journal of Thoracic and Cardiovascular Surgery, and he is a member of the Society of Thoracic Surgeons and International Thymic Malignancy Interest Group.
About Dr. Vincent (Wentao) Fang
Wentao Fang, MD, Professor Current position:Deputy Chief, Department of Thoracic Surgery, Shanghai Chest Hospital Chief, Division of Mediastinal Surgery, Shanghai Chest Hospital Chief Director, Clinical Center for Esophageal Diseases, Jiaotong University Expertise in General Thoracic Surgery: Full range of thoracic procedures. Exclusive experience in the following: 1. Minimally invasive (including Robotic) thoracic surgery. 2. Pulmonary resection for benign and malignant diseases. 3. Systemic lymph node dissection for esophageal cancer. 4. Anti-reflux procedures for GERD. 5. Thymectomy for thymoma and myasthenia gravis. Educational involvement Postgraduate program at the Shanghai Jiaotong University Medical School CME program in general thoracic surgery, Shanghai Chest Hospital Faculty member, Asian Thoracoscopic Surgery Education Program (ATEP) Academic positions: Secretary, Steering Committee member, International Thymic Malignancy Interest Group (ITMIG) Member, International Association of Study for Lung Cancers (IASLC) Member, International Society for Diseases of the Esophagus (ISDE) Executive committee member, Esophageal Cancer Committee, Chinese Anticancer Association Program Committee member, European Society of Thoracic Surgeons (ESTS) Faculty member, Asian Thoracoscopic Surgery Club (ATSC) Editorial Board Membership: 《Journal of Thoracic Diseases》Associate Editor in Chief《Annals of Thoracic Surgery》《Gastrointestinal Research》《World Journal of Gastrointestinal Surgery》《Chinese Medical Journal》《Chinese Journal of Surgery》《Chinese Journal of Gastrointestinal Surgery》International Advisory Board Member for《Asian Cardiovascular and Thoracic Annals.
About Dr. Joe Friedberg
Dr. Joseph Friedberg is currently the Chief of the Division of Thoracic Surgery and the Charles Reid Edwards Professor of Surgery at the University of Maryland. He was previously the founder and Director of the Penn Mesothelioma and Pleural Program and is now the Director of the University of Maryland School of Medicine Mesothelioma and Thoracic Oncology Treatment and Research Center. He graduated Summa Cum Laude from the University of Pennsylvania College of Engineering and Applied Science, majoring in bioengineering, and subsequently graduated Cum Laude from Harvard Medical School. He completed his general surgery training at the Massachusetts General Hospital and his thoracic track cardiothoracic fellowship at the Brigham and Women’s Hospital. He holds multiple patents, has been a funded researcher, has published extensively and lectures both nationally and internationally. His primary clinical and research interest is improving current treatments, and developing new treatments, for mesothelioma and other pleural malignancies.
About Dr. Nicolas Girard
Nicolas Girard is Professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and Senior Attending Physician in the Thoracic Oncology Service of the Hospices Civils de Lyon. He serves as the Head of Research of the Institute of Oncology at the Hospices Civils de Lyon. Nicolas Girard received his MD degree from the University of Lyon in 2005. He then performed fellowships in Respiratory Medicine and Medical Oncology. From 2007 to 2009, he joined the laboratory of Dr. William Pao at Memorial-Sloan Kettering Cancer Center, in New York, where he specialized in the field of Molecular Biology and Personalized Medicine. Among multiple projects, he performed a comprehensive genomic analysis of thymic malignancies. Nicolas Girard, as Vice-President of ITMIG from 2010 to 2014, has served in several committees, including the prospective database, the virtual tumor bank, and the research committees; more recently he has been involved in the development of the biology/basic science group. Nicolas Girard is coordinator of RYTHMIC, a French nationwide network for the management of these tumors. Nicolas Girard has published more than 100 articles and 15 book chapters in the field of thoracic oncology, and is a member of the editorial board of the Journal of Thoracic Oncology and Lung Cancer.
About Dr. Jim Huang
Dr. Huang is an Associate Professor and Associate Attending Surgeon at Memorial Sloan Kettering Cancer Center, where he also serves as the Program Director for Thoracic Surgery. After receiving his medical degree at Columbia, he received is surgical training in general surgery at the Brigham and Women’s Hospital, and thoracic surgery at Memorial Sloan Kettering Cancer Center. Dr. Huang maintains an active research interest in thoracic malignancies with a focus on multimodality therapies and outcomes research. He was a founding member of the International Thymic Malignancy Interest Group and Co-Chair of the Inaugural Meeting, and has served as the Chair of the International Database Committee, as well as Past Treasurer and Chair of the Finance Committee.
About Dr. Marlies Keijzers
Marlies Keijzers is a resident in Surgery at Viecuri Medisch Centrum in Venlo, The Netherlands. After obtaining her medical degree she started as a PhD-fellow at the department of Cardiothoracic Surgery at Maastricht University Medical Centre and expanded her research towards thymic malignancies in Prof. Marc de Baets and Prof. Jos Maessen’s research group. She obtained her PhD in july 2016. Marlies Keijzers became a member of International Thymic Malignancy Interest Group (ITMIG) in 2012. She gave oral presentations at the Fukuoka Meeting regarding robotic thymectomy and at the Bethesda meeting about ‘the detection of human polyomavirus 7 in thymic malignancies’. Currently she is the co-chair of the membership committee and a member of the website committee of ITMIG.
About Dr. Robert Korst
Dr. Korst graduated from the University of Connecticut School of Medicine in 1989, and completed his general surgery training in the University of Connecticut Integrated Program in General Surgery. Halfway through this training, he spent two years as a research fellow in the Pulmonary Branch of the National Heart Lung and Blood Institute in Bethesda, MD, where he performed research in molecular biology and gene transfer techniques and applications. He then trained in thoracic surgery in the Thoracic Streamed Program at Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University.
Following training, Dr. Korst joined the faculty at Memorial Sloan-Kettering Cancer Center where he performed both clinical thoracic surgery as well as translational research in gene transfer applications. Following eight years at both MSKCC and Cornell, he accepted a position to build a general thoracic surgery program at The Valley Health System, a tertiary care health system located in northern New Jersey, where he currently serves as the Director of thoracic surgery, as well as the Director of the Daniel and Gloria Blumenthal Cancer Center.
About Dr. Patrick Loehrer
Biography Coming Soon.
About Dr. Edith Marom
Dr. Edith M. Marom is a Professor of Diagnostic Radiology and Chair of the Chest Imaging Section at the Chaim Sheba Medical Center, Tel Hashomer, Israel, affiliated with the Tel Aviv University. Dr. Marom completed her MD studies, Magna Cum Laude, at the Sackler School of Medicine in the Tel Aviv University, her radiology residency at Rabin Medical Center, Israel, followed by a Thoracic Radiology Fellowship at Duke University Medical Center in Durham NC where she then worked for three additional years, and then worked for 12 years at the University of Texas, MD Anderson Cancer Center. Her clinical work includes the imaging diagnosis and follow-up of neoplastic and inflammatory diseases affecting the thorax as well as lung cancer screening. Dr. Marom’s work includes over 140 manuscripts, 32 book chapters, with special interest in neoplastic diseases in the thorax, with a particular interest in lung cancer and treatment-related complications, and thymic epitherlial malignances. Dr. Marom serves as a reviewer for 10 professional leading journals in the field, has leading roles in national and international professional societies and strives to improve the knowledge of thymic epithelial malignancies through her work in ITMIG’s education committee.
About Dr. Alex Marx
CV of Alexander Marx, MD University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany A. Current title and address Professor of Pathology, Chairman Institute of Pathology, University Medical Centre Mannheim University of Heidelberg D-68167 Mannheim, Germany B. Academic degree 1982, Medical Doctor (MD), University of Bonn, Bonn, Germany C. Studies and Positions 1975-1981 Medical School, University of Bonn, Bonn, Germany 1979-1982 MD Thesis, Institute of Physiological Chemistry, University of Bonn, Bonn Germany 1982-1983 Internship, Pediatrics, Children’s Hospital, St. Augustin, Germany 1984-1986 Assistant in Pathology and Physiology, University of Ulm, Ulm Germany 1987-1995 Assistant, 1995-1999 Assistant Professor,1998-2006 Vice-chairman (to Prof. Müller-Hermelink), 1999-2006 Associate Professor, Institute of Pathology, University of Würzburg, Germany 2006-present Director, Institute of Pathology, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany Main Research Interests: – Pathology, immunology and molecular biology of thymic tumors and of sarcomas – Cellular and molecular pathogenesis of the autoimmune disease, Myasthenia Gravis D. Honors 08-2001 Visiting Professorship, New York University, New York City, NY, USA 2015 Co-Editor, WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, IARC Press, Lyon, France 2008-2016 Reference pathologist, MGTX trial (Thymectomy in non-thymomatous Myasthenia gravis) 2013-2016 Co-chair, pathology group, TCGA project (thymoma, thymic carcinoma).
About Dr. Nuria Novoa
Nuria M. Novoa Valentín Adress: Paseo de San Vicente 58-172. 37007 Salamanca. Spain Telephone/Fax: +34923291100-Ext 55383 e-mail: email@example.com Professional experience Positions: Consultant Thoracic Surgeon, University Hospital of Salamanca, General Thoracic Surgery Service. Assistant Professor, University of Salamanca, Thoracic Surgery Department. Surgeon in charge of Education Activities of the General Thoracic Surgery Residency Program at the University Hospital of Salamanca. Co-chair of the ESTS QOL and Patient Safety Working Group ITMIG Communication Committee Chair Clinical Training: General Thoracic Surgery Program (1994). Hospital Gregorio Marañón. Madrid. Spain University period: Qualified PhD in 2001 at the University of Salamanca, Spain. Medical School: Universidad Autónoma de Madrid, Spain. 1989.
About Dr. Meinoshin Okumura
Education 1978-1984 Osaka University School of Medicine Professional experience 1984-1990 Resident of surgery, Department of Surgery, Osaka University Hospital and affiliated hsopitals 1990-1992 Research fellow, Department of Surgery, Osaka University Hospital 1993-1996 Post-doctoral fellow, Howard Hughes Medical Institute, and Department of Pathology, Washington University, St. Louis, MO, USA 1996-2002 Assistant Professor, Department of Surgery, Osaka University Hospital 2002-2004 Chief surgeon, Department of Surgery, National Kinki Chuo Hospital 2004 Associate Professor, Department of Surgery, Osaka University Hospital 2007- Professor, Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka University Hospital Qualification Board of surgery in Japan, Board of general thoracic surgery in Japan Speciality Surgery for lung cancer, thymic tumors, myasthenia gravis, and lung transplantation. Basic research for oncology, immunology, and regenerative medicine. Academic activity President, Japanese Association for Chest Surgery (JACS) Member of Council, Japan Surgical Society (JSS) Member of Board of Directors, Japanese Association of Thoracic Surgery (JATS) Member of Board of Directors, Japanese Lung Cancer Society President, Japanese Association for Research on the Thymus (JART) Manager of Office for Japanese National Registry of Lung Cancer Council member of European Society of Thoracic Surgeons (ESTS).
About Dr. Sukhmani Padda
Biography Coming Soon. Sukhmani (Suki) Padda MD is an Assistant Professor of Medicine in the Department of Medicine, Division of Oncology at Stanford University, with a specific interest in immunotherapy/tumor immunology and early phase clinical trials in thoracic oncology. She graduated from a 6-year medical program, Northeastern Ohio Medical University in 2007. The year following medical school, she did clinical research in early phase trials in thoracic malignancies with Dr. Heather Wakelee, Associate Professor of Medicine at Stanford University. She completed internal medicine residency and hematology/oncology fellowship at Stanford University in 2014. She is working on clinical trials of novel combinations in EGFR mutated non-small cell lung cancer (NSCLC) to prevent the development of resistance, and also combinations involving the repurposing of drugs in KRAS mutated NSCLC. She contributed to the development and is an active co-investigator of the clinical trial of a first-in-human class of immunotherapeutics, anti-CD47, in solid tumor patients. She has a significant interest in thymic malignancies, and has examined PD-L1 expression in a thymic malignancy tissue microarray and is currently examining the impact of paraneoplastic/autoimmune syndromes on clinical outcomes for thymoma patients using the retrospective International Thymic Malignancy Interest Group (ITMIG) database.
About Dr. Giovannella Palmieiri
Responsible of project of AIRC, CNR, AIFA and Italian National Health Institute • In last years her research is focused on Neuroendocrine growth control in TET (project financed by National Health institute in Programma Speciale-Progetto strategico) and she has for the first time demonstrated the efficacy of association of Octreotide Prednisone (New England Journal of Medicine 336: 263-65, 1997.) She has promoted cooperative study on rare disease organizing many conference. One of the most important is Updated on Thymus and Thymic disorders –Annals of Medicine vol. 31, 1999. Latest focus research on paraneoplastic syndrome with the redefinition of Good Syndrome. • In Naples and south Italy she is scientific responsible for a working group of oncologist, pathologist, immunologist, nuclear medical physicians, endocrinologist and neurologist to approach above all thymic disorders in a multidisciplinary way and also other rare tumours. • In last years she is focused to find new therapeutical approach in these disorders and than to redefine the rare paraneoplastic disease associated TET: good syndrome. • Principal investigator and participant of many Clinical Trial GCP compliance.
About Dr. Arun Rajan
Arun Rajan is a staff clinician in the Thoracic and Gastrointestinal Oncology Branch at the National Cancer Institute (NCI). He completed his residency in Internal Medicine and fellowship training in Hematology and Medical Oncology from SUNY Upstate Medical University in 2008. He then joined the Thoracic Oncology Branch at the NCI/National Institutes of Health in 2009. Dr. Rajan’s research has focused on the development of novel therapies for patients with non-small cell lung cancer and thymic epithelial tumors. He has served as the principal investigator or lead associate investigator of a number of phase II clinical trials for patients with thymic cancers that have evaluated the role of targeted therapies such as sunitinib, cixutumumab, belinostat, and milciclib. Dr. Rajan is a member of the Basic Science and Thymic Carcinoma working groups of ITMIG. He has participated in the development of ITMIG guidelines for the radiographic assessment of treatment response of thymic epithelial tumors. Dr. Rajan is also a member of the Thymoma Analysis Working Group of The Cancer Genome Atlas project on thymic malignancies.
About Dr. Gregory Riely
Dr. Gregory Riely is a medical oncologist in the Department of Medicine at Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College. His primary research focus is in clinical research of patients with non-small cell lung cancer. Dr. Riely received his BA from The Johns Hopkins University, and his PhD and MD degrees from Case Western Reserve University. He completed fellowship training in Medical Oncology at Memorial Sloan-Kettering Cancer. He has authored and co-authored numerous peer-reviewed research articles.
About Dr. Andreas Rimner
Andreas Rimner, M.D., is an Assistant Attending in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSKCC). A native of Germany, he earned his medical degree at the Eberhard Karls University of Tuebingen. In 2003, he joined the laboratory of Dr. Zvi Fuks for a postdoctoral fellowship in radiation biology, after which he went on to complete his residency in radiation oncology at MSKCC. In 2010, Dr. Rimner joined the faculty as the primary thoracic radiation oncologist in the Department of Radiation Oncology at MSKCC. He is an expert on radiation therapy for rare thoracic malignancies, including thymic malignancies and malignant pleural mesothelioma. He joined ITMIG in 2010 and has led the ITMIG Thymic Carcinoma Working Group since 2013. He is the recipient of the 2014 ITMIG Barbara Neibauer Award for the Best Paper on Thymic Carcinomas.
About Dr. Bill Robinson
The Robinson laboratory works in the fields of B cell biology, autoimmunity and inflammation. Dr. Robinson pioneered development of protein arrays, lipid arrays, and most recently high-throughput sequencing approaches to identify the targets of antibody responses, investigate mechanisms underlying disease, and to develop novel therapeutic approaches. Dr. Robinson is the PI of the NIH Stanford AMP Technology Center, Director of the Stanford Arthritis Initiative, and Co-Director of the Stanford-UCSF Arthritis Foundation Center of Excellence. He co-founded the Stanford Human Immune Monitoring Center, serves on the editorial boards of several journals, and serves on the Board of Directors of the American College of Rheumatology’s Rheumatology Research Foundation. He is an inventor on 23 patent applications, and technologies developed in his Stanford and VA laboratories have been licensed to nine companies in the biotechnology industry. He is the academic founder of Atreca, Inc, a biotechnology company developing therapeutic antibodies for cancer. Dr. Robinson was elected to the American Society for Clinical Investigation and the Henry Kunkel Society in 2010. Dr. Robinson received his MD and PhD degrees from Stanford University, and completed his clinical training in internal medicine at UCSF.
About Dr. Anja Roden
Dr. Roden is an Associate Professor of Pathology in the Department of Laboratory Medicine and Pathology at the Mayo Clinic Rochester, MN, US. Her areas of expertise include thoracic and surgical pathology. Dr. Roden also serves as the Medical Director of the Immunostains Laboratory of the Department. Dr. Roden studied medicine at the Humboldt University of Berlin and the Technical University of Dresden in Germany. After her residency in General Surgery and research training in cancer immunology, Dr. Roden completed her residency in Anatomic and Clinical Pathology at the Mayo Clinic in Rochester. She completed her fellowship in Surgical Pathology at the Mayo Clinic and received a Mayo scholarship in Pulmonary Pathology. Dr. Roden focuses her research on thymic epithelial neoplasms and mediastinal malignancies. In 2009 she joined ITMIG and serves as Vice President since 2014. Dr. Roden is also a member of the virtual thymoma panel of pathology laboratories of the Netherlands. She recently participated in the development of the dataset for Thymus Epithelial Tumours organized by the International Collaboration on Cancer Reporting. She has multiple publications on prognostic factors, histologic classification, staging, cell kinetic parameters and subtypes of thymic epithelial tumors amongst others.
About Dr. Joseph Shrager
Dr. Shrager is Professor and Chief of the Division of Thoracic Surgery at Stanford University School of Medicine and Thoracic Oncology Clinical Care Program Leader in the Stanford Cancer Institute. He earned his MD at Harvard, trained in Surgery at the University of Pennsylvania, and completed his Thoracic Surgery training at Massachusetts General Hospital. Dr. Shrager has a busy Thoracic Surgery practice focused upon lung cancer, mediastinal disease, and emphysema. He has been listed yearly for over a decade in Castle-Connolly’s peer-evaluation-based, national “top doctor” listings. His expert status among his peers is also evidenced by his position on the editorial board of the Annals of Thoracic Surgery. His clinical research bibliography, which includes over 150 publications, extends over many areas of thoracic surgery and oncology including minimally invasive approaches to thymectomy and lung cancer. His funded basic/translational research has concentrated upon the responses of the respiratory muscles to various disease states and interventions. His group was the first to identify diaphragm atrophy associated with mechanical ventilation. This laboratory work has been published in journals such as The New England Journal of Medicine, The Journal of Thoracic and Cardiovascular Surgery, and The American Journal of Respiratory and Critical Care Medicine.
About Dr. Joshua Sonett
University Medical Center, where after two years he received scholarship support for his studies, graduating with highest honors as a member of the Alpha Omego Alpha Honorary Medical Society. Pursing a career in surgery, he trained in General Surgery at the University of Massachusetts Medical Center, where his clinical course and training were accelerated by one year, allowing him to pursue research interests in Cardiothoracic Surgery. His formal training was completed in Cardiothoracic Surgery and Thoracic Transplantation at the University of Pittsburgh Medical Center. Additional training was attained in Thoracic Oncology and Surgery at the Sloan Kettering Memorial Cancer Center. In July of 2001, Dr. Sonett joined the faculty at Columbia University NewYork-Presbyterian University Hospital as Program and Surgical Director of the New-York Presbyterian Lung Transplant Program and became Chief of General Thoracic Surgery in July 2006. As Professor of Surgery, he holds the Weiskopf chair in surgical oncology and leads the Price Center for Comprehensive Chest Care. Dr. Sonett is well published in peer reviewed journals with extended interest in minimally invasive lung, esophageal, and thymic surgery: with a special recognized focus in the multidisciplinary care of patients with advanced esophageal, lung cancer, Myasthenia Gravis, and lung transplantation. Dr. Sonett has had the privilege of being the primary surgeon operating on Former President Bill Clinton and listed as New York Top Doctors for the past 14 years.
About Dr. Heather Wakelee
Dr. Heather Wakelee is an Associate Professor of Medicine at Stanford University in the Division of Oncology where she leads the thoracic medical oncology research program and has authored or co-authored over 130 medical articles on thoracic malignancies. She attended Princeton University and then went to medical school at Johns Hopkins University. She returned to her native California for internal medicine residency and fellowship training in medical oncology at Stanford University. Dr. Wakelee’s focus is in clinical research in thoracic malignancies including lung cancer and thymic malignancies. Dr. Wakelee has led multiple investigator-initiated protocols looking at bevacizumab and other anti-angiogenic agents. Additional areas of interest include drugs and drug combinations focused on overcoming EGFR and ALK inhibitor resistance, Met inhibitors and novel immune modulatory agents. She serves on the steering committee and is the chair of the Research Working Group of the International Thymic Malignancies Interest Group (ITMIG) and has written and conducted multiple phase II trials of novel agents in this rare disease entity. She is very active in the American Society of Clinical Oncology (ASCO) and also serves on the Board of Directors of the International Association for the Study of Lung Cancer (IASLC).